UNH: When the Smart Money Goes In.

Dear Investors,

Zee here. Every day, we sift through mountains of market news, charts, and company reports. Most of it never sees the light of day, until now. Instead of letting all that research sit in our notebooks, we’re turning it into bite-sized, easy-to-read nuggets for you.

That’s why we’re starting KISS: Kintsugi Investing Stock Saturdays — your weekly dose of sharp, bite-sized stock insights, served fresh every Saturday.

This is our very first issue. Enjoy!

After two decades in the investing game, you develop a sixth sense for when something big is happening. It's that feeling when you see multiple chess pieces moving on the board simultaneously, all pointing toward the same conclusion.

That's exactly what's happening with UnitedHealth Group (UNH) right now. And frankly, it's the kind of opportunity that doesn't come along very often, a genuinely high-quality business trading at what might be significantly undervalued levels.

Let me walk you through what's been happening behind the scenes, because the smart money isn't just buying UNH... they're backing up the truck.

The Oracle of Omaha's $1.6 Billion Vote of Confidence

Warren Buffett's Berkshire Hathaway just disclosed a massive new position in UnitedHealth, buying more than 5 million shares worth approximately $1.6 billion at the end of June. This isn't some small speculative bet, this is Berkshire making UNH a top-10 holding.

But here's what makes this move so interesting: Buffett previously owned UnitedHealth shares between 2006 and 2009, before selling his entire stake in 2010 amid a broader retreat from health insurers. The man who famously says his favorite holding period is "forever" sold UNH 15 years ago.

So why is he back now?

The timing tells us everything. Buffett doesn't chase momentum or buy into hype. He buys when others are selling, when great businesses are temporarily out of favor, when the market has created genuine mispricings.

And right now, UnitedHealth's stock is trading around its five-year lows, despite the company continuing to generate massive cash flows and dominate the healthcare industry.

It's Not Just Buffett: The All-Stars Are Loading Up

When you see one legendary investor making a big move, it's noteworthy. When you see all of them moving in the same direction, it's time to pay attention.

Here's the roster of investment legends who have been accumulating UNH:

The Hall of Fame Lineup:

• Warren Buffett: 5.03 million shares ($1.6B+ position)

• Dodge & Cox: 4.73 million shares (one of the most respected value shops)

• David Tepper: 2.27 million shares (the hedge fund king)

• Renaissance Technologies: 1.35 million shares (the quant legends)

• Michael Burry: Buying call options (the "Big Short" guy)

• Saudi Arabia's PIF: Also buying call options (sovereign wealth fund)

This isn't some random collection of investors. This is a murderer's row of the smartest money in the world, all making the same bet at the same time.

Dodge & Cox, for context, manages over $300 billion and has been in business for nearly a century. They don't chase trends they buy when value is genuinely mispriced.

David Tepper has generated 25%+ annual returns for decades and is worth $20+ billion. When he's buying, it's usually because he's found something the market is dramatically undervaluing.

And Michael Burry? The guy who predicted the 2008 financial crisis is buying call options on UNH. That's not a hedge that's a conviction play.

What's Everyone Else Missing?

So why are all these legendary investors piling into a stock that's been beaten down? What do they see that the broader market is missing?

The Perfect Storm of Temporary Problems:

UNH has been hit by a series of issues that look scary in headlines but are largely temporary from a business perspective:

1. The cyberattack fallout: UnitedHealth faced a major cyberattack last year that disrupted operations and cost billions. It was headline-grabbing, expensive, and completely temporary.

2. Rising medical costs: Post-COVID medical utilization has normalized, creating short-term margin pressure. This is cyclical, not structural.

3. Regulatory scrutiny: Healthcare is always under political pressure, but UNH's scale and efficiency actually make them more valuable during regulatory crackdowns, not less.

4. The executive tragedy: The shocking murder of UnitedHealthcare's CEO created negative media attention and raised questions about public perception of health insurers.

Each of these issues is real, but none of them changes UNH's fundamental business advantages. If anything, they've created a temporary valuation discount on one of the most dominant business models in America.

The Business That Prints Money

Let's talk about what UNH actually does, because this isn't your typical insurance company.

UnitedHealth Group operates what might be the most robust healthcare ecosystem in the world:

UnitedHealthcare (Insurance): The largest health insurer in America, covering 50+ million people. This generates predictable premium revenue and benefits from scale advantages that smaller competitors simply can't match.

Optum (Healthcare Services): This is the secret weapon. Optum provides pharmacy benefits, healthcare technology, and direct care services. It's growing rapidly and operates with higher margins than the insurance business.

Think of UNH as owning both the payment system and the infrastructure of American healthcare. They collect premiums, manage costs, own pharmacies, provide technology, and even deliver care directly through their network of clinics and services.

It's a vertically integrated healthcare monopoly that would be nearly impossible to replicate today.

The Numbers That Matter:

• Revenue: $370+ billion annually (larger than most countries' GDP)

• Operating margin: Consistently 6-8% on massive scale

• Free cash flow: $25+ billion annually

• Market position: #1 in most segments they compete in

This isn't a cyclical business or a growth story dependent on multiple expansion. This is a cash-generating machine with enormous competitive moats.

Why the Timing Is Perfect

Here's what makes this opportunity so compelling: UNH's temporary problems have created a valuation that doesn't reflect the business's fundamental strength.

The Valuation Disconnect:

• Trading at 5-year lows despite growing revenue and market share

• P/E ratio well below historical averages

• Dividend yield approaching 3%+ (and they've raised it for 15+ consecutive years)

• Free cash flow yield that's attractive even by Buffett's standards

When Buffett buys a stock, he's typically looking for businesses he can hold "forever" at prices that give him a margin of safety. The fact that he's buying UNH at current levels suggests he sees significant upside from here.

The Optum Advantage Nobody Talks About

Here's what most investors miss about UNH: The Optum business is quietly becoming one of the most valuable healthcare assets in America.

Optum isn't just a healthcare services company it's becoming the operating system for American healthcare:

• OptumHealth: Direct primary care, urgent care, and specialty services

• OptumInsight: Healthcare data and technology solutions used by competitors

• OptumRx: Pharmacy benefits management serving 65+ million people

The beauty of this model is that Optum generates revenue whether UNH's insurance business grows or shrinks. They're selling picks and shovels to the entire healthcare industry, including their competitors.

Optum's revenue growth has been outpacing the insurance business, and it operates with higher margins. As this business continues scaling, it could become more valuable than the insurance operations.

Warren Buffett loves businesses that become more valuable over time while throwing off cash. Optum fits that profile perfectly.

The Regulatory Angle Everyone Gets Wrong

One concern about UNH is regulatory risk, the fear that government intervention could hurt profitability or break up the business.

But here's the counterintuitive reality: UNH's scale and integration actually make them more valuable during regulatory crackdowns, not less.

When politicians talk about controlling healthcare costs, they need partners who can actually deliver results at scale. UNH is the only company with the size, data, and infrastructure to implement nationwide healthcare policies effectively.

Think about Medicare Advantage, where UNH dominates. The government wants private companies to manage Medicare more efficiently than traditional government programs. Who else can do this at UNH's scale?

Instead of being a regulatory target, UNH often becomes the regulatory solution.

The Call Options Tell a Story

Here's a detail that shouldn't be overlooked: Both Michael Burry and Saudi Arabia's sovereign wealth fund are buying call options on UNH, not just stock.

Call options are a leveraged bet on upside. When sophisticated investors buy calls instead of stock, they're expressing high confidence that the stock will move significantly higher within a specific timeframe.

This suggests these investors don't just think UNH is undervalued they think it's dramatically undervalued and likely to recover quickly once the temporary headwinds clear.

Burry, in particular, is famous for making concentrated bets when he sees major mispricings. His call option strategy on UNH suggests he sees substantial upside potential from current levels.

What Could Go Right

While everyone focuses on UNH's problems, let's consider what could drive the stock higher:

Near-term Catalysts:

• Medical cost normalization as post-COVID utilization stabilizes

• Optum growth acceleration as healthcare digitization continues

• Share buybacks funded by massive free cash flow generation

• Dividend increases (15+ year track record)

Long-term Drivers:

• Aging demographics increasing healthcare demand

• Continued market share gains in Medicare Advantage

• Optum becoming the infrastructure layer for U.S. healthcare

• Potential breakup value if regulatory pressure increases

The Buffett Effect: Don't underestimate the psychological impact of Berkshire's investment. When the world's most famous investor backs up the truck on a beaten-down stock, it often marks the beginning of a major recovery.

The Risk Everyone's Talking About

Let's be honest about the downside risks, because no investment is perfect:

Legitimate Concerns:

• Healthcare regulation is always evolving and could impact margins

• Medical costs could continue rising faster than premium increases

• Public perception of health insurers remains challenging

• Execution risk as the business becomes more complex

The Counterargument: UNH has navigated regulatory changes for decades and consistently emerged stronger. Their scale, data advantages, and integrated model make them more resilient than pure-play insurers.

Rising medical costs affect all insurers, but UNH's size and Optum integration give them better tools to manage these costs than competitors.

Why This Feels Like 2008-2009 All Over Again

For those of us who lived through the financial crisis, UNH's current situation has a familiar feel. Great businesses getting thrown out with the bathwater. Legendary investors quietly accumulating while headlines focus on temporary problems.

Buffett made some of his best investments during that period, buying when others were selling, focusing on business fundamentals while the market obsessed over short-term news.

His UNH investment has that same character: a dominant business facing temporary headwinds, trading at valuations that don't reflect long-term earning power.

The 20-Year Perspective

After two decades of investing, you learn to distinguish between temporary problems and permanent impairments. UNH's current challenges feel overwhelmingly temporary:

• Cyberattacks can be fixed with better security

• Medical costs are cyclical and manageable at scale

• Regulatory pressure creates barriers to entry, not threats to existence

• Public relations challenges don't change the fundamental need for health insurance

Meanwhile, the long-term trends all favor UNH:

• Aging population needs more healthcare

• Healthcare complexity increases the value of integration

• Technology disruption favors companies with scale and data

• Regulatory compliance favors large, sophisticated operators

What Smart Money Does Next

When you see this level of legendary investor alignment, the playbook is usually straightforward:

1. Follow the smart money while others are still selling

2. Size the position appropriately: this isn't a speculative bet, it's a high-conviction value play

3. Think in years, not quarters: temporary problems require patient capital

4. Focus on business fundamentals: cash flow, competitive advantages, market position

Buffett didn't build a $1.6 billion position in UNH because he thinks it's fairly valued. He built it because he sees significant upside from current levels.

The question isn't whether UNH will recover, businesses this dominant usually do. The question is whether you'll have the conviction to buy when the headlines are negative and the smart money is accumulating.

The Bottom Line

Opportunities like UNH don't come along very often. High-quality businesses, dominant market positions, massive competitive moats, trading at significant discounts to intrinsic value.

When Warren Buffett, David Tepper, Michael Burry, and Saudi Arabia's sovereign wealth fund all see the same opportunity, it's usually worth paying attention.

The temporary problems are real but manageable. The business fundamentals remain strong. The valuation offers a genuine margin of safety.

After 20 years in this game, these are the setups that create generational wealth. Not the hot growth stocks everyone's talking about, but the proven winners that temporary problems have made temporarily cheap.

The smart money is already moving. The question is whether you'll join them while the opportunity still exists.

 
P.S. If you found this article helpful, I want to personally invite you to our Market Quickies Live Session next Tuesday, 19th August 2025, from 8:30–9:30 PM GMT+8. We’ll be unpacking fresh data showing why August and September have historically been the market’s trickiest months and how you can take advantage of it. It’s going to be an interactive, so bring your questions, your curiosity, and maybe even your skepticism, you’ll walk away with insights you can use immediately.

Disclaimer:
All information here is for educational purposes only. This is not financial advice. Please do your own research and speak with a licensed advisor before making any investment decisions. Past performance is not indicative of future returns.